Uber stock surges after Nvidia partnership announcement
CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a healthcare company with a market capitalization of $34 million, has purchased an additional $500,000 worth of Ethereum (ETH), bringing its total investment in the cryptocurrency to $1.5 million, the company announced Friday. According to InvestingPro data, the company’s stock has shown remarkable momentum with a 215% return over the past six months.
The acquisition was executed under Cosmos Health’s previously announced $300 million digital assets facility, which forms part of the company’s strategy to diversify its balance sheet and incorporate blockchain technology in healthcare and digital wellness sectors.
Greg Siokas, CEO of Cosmos Health, said the company is seeing gains from its earlier Ethereum investments and believes there is potential for further appreciation with increased usage and adoption.
"We view select digital assets such as Ethereum not only as long-term investments, but also as potential enablers of secure, decentralized healthcare solutions," Siokas stated in the press release. While InvestingPro analysis indicates the company is currently undervalued, it also highlights challenges with gross profit margins at just under 10%.
Cosmos Health, incorporated in 2009, operates as a diversified healthcare group with interests spanning pharmaceutical and nutraceutical brands, manufacturing, and distribution. The company owns several proprietary brands including Sky Premium Life and Mediterranation.
Through its subsidiary Cana Laboratories S.A., the company manufactures pharmaceuticals, food supplements, and other healthcare products within the European Union under European Good Manufacturing Practices certification.
The company distributes pharmaceuticals and parapharmaceuticals to retail pharmacies and wholesale distributors through subsidiaries in Greece and the UK, and has recently expanded into telehealth through the acquisition of Texas-based ZipDoctor, Inc.
In other recent news, Cosmos Health Inc. reported a revenue increase of 11.7% for the first half of 2025, reaching $28.46 million, compared to the same period in 2024. The company’s gross profit also saw a significant rise of 53%, totaling $3.21 million, attributed to a focus on higher-margin branded products. Additionally, Cosmos Health announced the appointment of Theodoros C. Karkantzos to its board of directors, bringing over 15 years of experience in investment and business development. The company’s shareholders approved an amendment to increase the number of authorized shares to 1.5 billion common shares and 300 million preferred shares, effective upon filing with the Secretary of State of Nevada. Furthermore, Cosmos Health’s subsidiary, SkyPharm S.A., entered an exclusive distribution agreement with Diyar United to market its Sky Premium Life nutraceuticals in Kuwait. The company also released its CEO’s annual letter to shareholders, highlighting its strategic vision and recent accomplishments. These developments come as Cosmos Health continues to expand its reach and strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.